Biotech Values

[Titan V]

NDRA—Back to NAFLD

Widespread screening is not currently feasible given that a definitive diagnosis of NASH can only be made through identification of the characteristic histopathologic pattern on liver biopsy. While liver biopsy remains the gold-standard, its disadvantages are well known,” Saumya Jayakumar, MD, from the University of California in San Diego, and colleagues wrote. “There is a pressing unmet medical need for reliable and accurate noninvasive tools to evaluate steatosis and fibrosis in patients with NASH, and to monitor response to treatment.”

https://www.healio.com/hepatology/steatohepatitis-metabolic-liver-disease/news/online/%7Bb17ffd08-c424-49d3-817e-c58975d4ff6e%7D/nash-study-validates-liver-stiffness-by-mre-mri-pdff-as-viable-biomarkers